Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C32H63NO3
Número CAS:
Peso molecular:
509.85
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
C14 Ceramide (d18:1/14:0), Avanti Research™ - A Croda Brand 860514P, powder
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 25 mg (860514P-25mg), pkg of 1 × 5 mg (860514P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 860514P
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
OC[C@]([H])(NC(CCCCCCCCCCCCC)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
InChI
1S/C32H63NO3/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-31(35)30(29-34)33-32(36)28-26-24-22-20-17-14-12-10-8-6-4-2/h25,27,30-31,34-35H,3-24,26,28-29H2,1-2H3,(H,33,36)/b27-25+/t30-,31+/m0/s1
InChI key
ZKRPGPZHULJLKJ-JHRQRACZSA-N
General description
Ceramide synthesis is majorly driven by de novo pathway involving the palmitoyl-CoA and L-serine, and also by salvage pathway via recycling of complex sphingolipids. The ceramide transporter, Cert mediates the transfer of C14 from smooth endoplasmic reticulum to Golgi. Ceramide synthase CerS6 enzyme is involved in the synthesis of C14 ceramide.
Application
C14 Ceramide (d18:1/14:0) is suitable for use
- as a standard in high-performance liquid chromatography/tandem mass spectrometry (LC/MS2) for ceramide quantification from muscel biopsies
- in lipid monolayer preparation for biophysical studies
- in the morphological and dimensional evaluation studies
Biochem/physiol Actions
Ceramides regulate biological processes including proliferation, differentiation and apoptosis. In the cystic fibrosis patients, elevated levels of C14 ceramide is observed. It is also a potential biomarker for hepatic steatosis (HS) and C14 ceramide levels correlate with the aspartate aminotransferase (AST) / alanine transaminase (ALT) ratio. Tumor necrosis factor α (TNFα) mediates increase in the C14 levels. Fumonisin B1 prevents the C14 accumulation.
Packaging
5 mL Amber Glass Screw Cap Vial (860514P-25mg)
5 mL Amber Glass Screw Cap Vial (860514P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Clase de almacenamiento
11 - Combustible Solids
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain
Garic D, et al.
Progress in Lipid Research (2019)
Ceramide N-acyl chain length: a determinant of bidimensional transitions, condensed domain morphology, and interfacial thickness
Dupuy F, et al.
Langmuir, 27(7), 3783-3791 (2011)
Association between Plasmatic Ceramides Profile and AST/ALT Ratio: C14: 0 Ceramide as Predictor of Hepatic Steatosis in Adolescents Independently of Obesity
Maldonado-Hernandez J, et al.
Canadian journal of gastroenterology & hepatology, 2017 (2017)